MedTrace Logo

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

NCT02129751 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2025-09-17

No results posted yet for this study

Summary

Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety

Conditions

Interventions

DRUG

bupropion hydrobromide

study drug

DRUG

Placebo

placebo arm

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Varsha Bhatt · Bausch Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2029-07-31
Completion
2029-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129751 on ClinicalTrials.gov